Bioscience West Map Plots Life Science Industry Growth In California
Silicon Maps, Inc. the leading promotional industry Map design firm for Life Sciences has launched the new BIOSCIENCE WEST Map & Calendar campaign for 2015; the 15 edition depicts a robust industry featuring over 150 companies.
Trending on the Topix Network
Monday Apr 14
View Press Release
AdvilA Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick off a Nationwide "Relief" Tour #ReliefinAction reignites in its second year of helping volunteers who don't let pain stop them from helping others with a Mobile Relief Center tour and the #ReliefinAction Pledge )--Pfizer Consumer Healthcare, ... (more)
Mon Apr 07, 2014
Grace Launches ProVance Disposable Protein A Chromatography Columns to Help Reduce Costs and ...
Columbia, MD, USA, April 4, 2014 / B3C newswire / - W. R. Grace & Co. announced the launch of ProVance pre-packed Protein A columns at Bioprocessing Development Week in San Diego, CA USA and the Bioprocess International Conference in Prague, Czech Republic.
Fri Apr 04, 2014
BDP Week Highlights The Importance Of Communication In Pharma
At this year's Biopharmaceutical Development and Production Week, March 24-27 at the Hilton Bayfront Hotel, I attended several sessions that focused on how to strengthen the relationship between partners in the pharmaceutical industry.
Wed Apr 02, 2014
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of...
The primary endpoint of the study was achieved: there was a statistically significant difference at 24 months in change from baseline height between patients treated with GENOTROPIN and those in the untreated control group, as measured by height standard deviation score .
Re: It's not "promise"; it's results in the here and now
An excellent article, we are glad that Pfizer is finally working on this. EMR data can be very powerful tool from pharmaceutical company's perspective.
Tue Apr 01, 2014
Q1 Productions Hosting 3rd Annual Regulatory Writing and Submission Conference
Chicago April 1, 2014 - For the third consecutive year, Q1 Productions will be hosting the Regulatory Writing and Submission Conference on May 8-9, 2014 in Alexandria, Virginia, offering medical and regulatory writers and submissions specialists an opportunity to meet with the industry's biggest names and receive the most relevant information ... (more)
Mon Mar 31, 2014
Pfizer Inc. Statement On FDA Approval Of Over-the-Counter Nexium 24HR
Pfizer Statement on U.S. FDA Approval of Over-the-Counter NexiumA 24HR NEW YORK-- --Today the U.S. Food and Drug Administration approved over-the-counter NexiumA 24HR marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.
Sun Mar 30, 2014
Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold ...
Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold Mine and Ford Raised CEO Alan Mulally's Compensation by 11% Ariad Pharmaceuticals Inc. - For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA ARIA shares closed up 5% on Friday with about 20.6 million shares traded.
Thu Mar 27, 2014
DiscoveRx Corporation And Collaborators Present Data On Safety,...
DiscoveRx Corporation, through its wholly owned Bioseek subsidiary, today announced new findings regarding the safety and toxicity of a variety of chemicals, pharmaceuticals and other materials, tested via the Predictive Tox panel in the company's BioMAPA Systems platform.
Pfizer Inc.'s Experimental Anti-Cholesterol Drug Bococizumab Meets Main Study Goals
Pfizer Inc. today announced the Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab, the proposed generic name for RN316.
In A Subanalysis, The Benefits Of Eliquis (apixaban) Vs. Warfarin In...
However, this subanalysis found consistent results for Eliquis versus warfarin in reducing the risk of stroke, regardless of blood pressure control.1 These data will be presented Saturday, March 29, at the American College of Cardiology's 63rd Annual Scientific Session in Washington, D.C. "High blood pressure is a risk factor for stroke in patients ... (more)
Wed Mar 26, 2014
Diabetes epidemic, settlement of patent suit means bright future for chromium, Nutrition 21 says
The market for chromium is growing, driven by the ongoing tide of obesity and diabetes, said Bill Levi of Nutrition 21, which supplies Chromax, a patented form of chromium picolinate.
Pfizer Inc. Notches Another Successful Phase 3 Trial With Genotropin
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPINA In Very Young Children Born Small For Gestational Age NEW YORK-- --Pfizer Inc. announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPINA on the height in small-for-gestational-age children 24-30 months old.
The Motley Fool
Today's Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Tue Mar 25, 2014
Conatus: An Undervalued Biotech With A Looming Short Squeeze
Conatus' sell-off represents an opportunity for considerable near-term price appreciation as shorts begin covering before Thursday's earnings announcement.
NYSE most active: Bank of America (NYSE:BAC), Pfizer Inc. (NYSE:PFE), ...
NYSE most active: Bank of America , Pfizer Inc. , Verizon Communications , Petroleo Brasileiro Petrobras .
Pfizer Inc.'s XALKORI Beats Chemo For Previously Untreated Patients In Phase 3 Study
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORIA Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer NEW YORK-- --Pfizer Inc. announced today that PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase inhibitor XALKORIA , met its primary objective of significantly prolonging ... (more)
The Miami Herald
Health care, tech names lead decline in US stocks
In this Wednesday, March 19, 2014, file photo, Specialist Meric Greenbaum works at his post on the floor of the New York Stock Exchange.
Biotech Weakness Makes Indices Ill
Asian stock indices continued their rally last night despite a continued slowdown of manufacturing growth in China.